ArticleFrontiers in cell and developmental biology2026
Pharmacological combination of simvastatin and doxorubicin reduces tumor growth and lung metastasis in triple-negative breast cancer.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, lacking expression of estrogen, progesterone, and HER2 receptors, limiting the efficacy of targeted therapies. Patients with TNBC face a poor prognosis, with a median survival of less than 5 years. Drug repurposing has emerged as a promising strategy to improve therapeutic options and overcome resistance in TNBC. Methods: We evaluated the antitumor efficacy of simvastatin, a cholesterol-lowering drug, in combination with doxorubicin using MDA-MB-231 TNBC cells and spheroids, and an orthotopic mouse TNBC model. The cells and spheroids were treated with doxorubicin either individually or in combination with simvastatin to assess the effects on viability, migration, and invasion. Results: Conclusion: Our findings suggest that simvastatin enhances the therapeutic response of doxorubicin and may represent a valuable adjuvant strategy to control metastatic progression in TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.